Levels of TGF-β, which has anti-tumor effects in early-stage cancer but tumor–promoting effects in late-stage cancer, IL-10, and nitric oxide synthase 2 (NOS2) increase as tumors progress [225,226]. This evidence concerns the gene NOS2 and neoplasm.